Thermo Fisher Gets Dual Price Target Boosts as Stock Nears 52-Week High

By TrendSpider Editor

Thermo Fisher Scientific shares surged 2.99% to $693.39 on Thursday as two major Wall Street firms raised their price targets on the life sciences giant, with TD Cowen lifting its target to $760 and Morgan Stanley hiking to $730. The dual endorsements arrive with TMO trading just shy of its 52-week

Thermo Fisher Gets Dual Price Target Boosts as Stock Nears 52-Week High

Thermo Fisher Scientific shares surged 2.99% to $693.39 on Thursday as two major Wall Street firms raised their price targets on the life sciences giant, with TD Cowen lifting its target to $760 and Morgan Stanley hiking to $730. The dual endorsements arrive with TMO trading just shy of its 52-week high of $694.325, a dramatic recovery from the 52-week low of $435.27 that underscores the stock's powerful momentum over the past year. With an average price target of $745 across recent analyst actions, Wall Street sees additional upside from current levels.

Key Drivers of the TMO Stock Move

• Main Catalyst: Morgan Stanley analyst Tejas Savant reaffirmed a "buy" rating and raised the price target from $650 to $730, while TD Cowen analyst Dan Brennan also confirmed a "buy" and lifted his target from $675 to $760. Both actions represent meaningful upward revisions, with the average new target sitting at $745.
• Bull Case: The stock is pressing against its 52-week high of $694.325, and with the consensus average price target at $745, there is still roughly 7.5% implied upside from the current price of $693.39. Two independent buy confirmations with raised targets signal broad conviction among institutional research desks.
• Bear Case: Neither action represents a fresh upgrade, only confirmations of existing buy ratings. With TMO already approaching its 52-week high, the stock may face natural technical resistance at these levels, and any disappointment in upcoming results could pressure shares given the elevated positioning.

The timing of these price target increases suggests analysts are growing more confident in Thermo Fisher's business trajectory heading into the back half of 2026. The stock has staged an extraordinary rally from its 52-week low of $435.27, gaining over 59% to reach current levels near $693.39. With two buy-rated analysts now anchoring targets at $730 and $760 respectively, the forward setup looks constructive as long as TMO can hold its ground near all-time highs. Investors will be watching closely to see whether the stock can break decisively above the $694.325 resistance level on sustained volume and whether upcoming fundamental catalysts can justify the premium valuation implied by the new targets.

TMO Analyst Ratings and Price Targets

Two analyst actions were recorded on October 15, 2026, both confirming existing buy ratings with meaningfully higher price targets:

• Morgan Stanley (Tejas Savant): Confirms "buy" rating | Price target raised to $730 from prior $650
• TD Cowen (Dan Brennan): Confirms "buy" rating | Price target raised to $760 from prior $675

The consensus average price target across both actions stands at $745, representing upside of roughly 7.5% from the current price of $693.39. There were zero upgrades and zero downgrades recorded; both actions were rating confirmations accompanied by target increases.

TMO Seasonality

The fourth quarter has historically been an active period for life sciences capital equipment purchasing, as institutional and research customers look to deploy remaining budget allocations before year end. Analyst confidence heading into this seasonal tailwind may partially explain the timing of the dual price target increases in mid-October.

TMO Relative Performance

TMO's 2.99% gain on Thursday places it firmly in outperformer territory relative to the broader life sciences and healthcare equipment sector for the session. The stock's position near its 52-week high of $694.325, compared to a 52-week low of $435.27, reflects one of the more robust recoveries among large-cap healthcare names over the trailing twelve months, suggesting TMO has significantly outpaced many of its peers during this period.